<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060316</url>
  </required_header>
  <id_info>
    <org_study_id>T2R-001</org_study_id>
    <nct_id>NCT04060316</nct_id>
  </id_info>
  <brief_title>GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery</brief_title>
  <official_title>Efficacy, Safety, and Tolerability of Adjuvant GLS-1200 Topical Nasal Spray in the Prevention of Acute Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will evaluate the safety, tolerability and effectiveness of GLS-1200&#xD;
      nasal spray in addition to the standard of care after endoscopic sinus surgery in people with&#xD;
      chronic sinusitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be assigned to treatment via nasal spray with either GLS-1200 or placebo in&#xD;
      blinded manner in a 2:1 ratio. Treatment will commence 1 week post-operatively and continue&#xD;
      for 7 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures: treatment emergent adverse events by group will be summarized as frequencies by severity and relationship to treatment</measure>
    <time_frame>Post-op through week 16 post-FESS</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the incidence of post-operative acute rhinosinusitis relative to treatment assignment</measure>
    <time_frame>Post-op through week 16 post-FESS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess week 16 post-FESS Sino-Nasal Outcome Test-22 (SNOT-22) group scores change from baseline relative to treatment assignment</measure>
    <time_frame>Week 16 post-FESS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess antibiotic usage relative to treatment assignment</measure>
    <time_frame>1 week post-op through week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Sinusitis Chronic</condition>
  <arm_group>
    <arm_group_label>GLS-1200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 ml of GLS-1200 (1 mg/ml in 0.9% saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 ml of 0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-1200</intervention_name>
    <description>GLS-1200 is given as a nasal spray using an atomizer</description>
    <arm_group_label>GLS-1200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is given as a nasal spray using an atomizer</description>
    <arm_group_label>Sterile Saline</arm_group_label>
    <other_name>Sterile Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older;&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Able and willing to comply with study procedures&#xD;
&#xD;
          -  Elective FESS&#xD;
&#xD;
          -  Able and willing to utilize an approved form of pregnancy prevention for women of&#xD;
             child bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or documentation of pregnancy by pre-operative pregnancy test&#xD;
&#xD;
          -  History of primary ciliary dyskinesia&#xD;
&#xD;
          -  Known allergy to quinine, quinidine or mefloquine&#xD;
&#xD;
          -  Know latex allergy&#xD;
&#xD;
          -  History of hematologic malignancy&#xD;
&#xD;
          -  History of bone marrow transplantation&#xD;
&#xD;
          -  Current or planned chemotherapy treatment for hematologic or solid tumor during study&#xD;
             period&#xD;
&#xD;
          -  FESS performed non-electively and /or in preparation for decontamination of the&#xD;
             sinuses related to cystic fibrosis or in preparation for chemotherapy, solid organ&#xD;
             transplantation, or bone marrow transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>484-965-9147</phone>
    <email>jmaslow@genels.us</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Project Manager</last_name>
    <email>dkane@genels.us</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Pablo Tebas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

